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RESEARCH ARTICLE
Central, Extraventricular and Atypical Neurocytomas: a
Clinicopathologic Study of 35 Cases from Pakistan Plus a
Detailed Review of the Published Literature
Zubair Ahmad, Nasir Ud Din*, Aisha Memon, Mohammad Usman Tariq,
Romana Idrees, Sheema Hasan
Abstract
Background: Central neurocytomas are rare neuronal neoplasms with a favorable prognosis. They are
typically located in the lateral ventricles of the brain and mostly histologically correspond to WHO grade II
with a Mib 1 labelling index of <2%. Similar tumors located in the cerebral hemispheres and spinal cord, for
example, are called “extraventricular neurocytomas”. A few tumors histologically show atypia, mitoses, vascular
proliferation and/or necrosis and a Mib 1 index >2 % and are designated as “atypical neurocytomas. Aim: The
aim of our study was to describe the common as well as unusual morphologic features and the role of various
immunohistochemical stains in the diagnosis of these rare tumors. Materials and Methods: We retrieved and
reviewed 35 cases diagnosed between 2001 and 2015. Results: Sixty percent of patients were males, and the mean
age was 26 years. 31 cases (88.6%) were intraventricular and 4(11.4%) were extraventricular. Histologically,
6 cases (17.1%) were compatible with “atypical neurocytomas”. All cases showed the classic morphology
comprising nests and sheets of uniform, round cells with uniform round to oval nuclei with finely speckled
chromatin and perinuclear cytoplasmic clearing (halos). All cases also showed delicate, fibrillary, neuropil-like
matrices. Other common histologic features included capillary-sized blood vessels in a branching pattern in
57.1%, foci of calcification in 34.3% and perivascular pseudorosettes in 20%. Rare findings included HomerWright or true rosettes in 8.6% and ganglioid cells in 2.9%. Synaptophysin was the most consistent and valuable
marker, being positive in almost all cases. GFAP positivity in tumor cells was seen in 25.7% of cases. Follow up
was available in 13 patients. Of these 9 had histologically typical and 4 had atypical tumors. Only 1 (with an
atypical neurocytoma) died, probably due to complications of surgery within one month, while 12 (including
3 with atypical neurocytomas) remained alive. Recurrence developed in 1 of these 12 patients (histologically
consistent with typical morphology) almost 9 years after surgery. Only 4 patients, including 2 with atypical
tumors, received postoperative radiotherapy, all with surgery in 2010 or later. Overall, prognosis was excellent
with prolonged, recurrence free survival and most patients, even without receiving radiation therapy, were alive
and well for many years, even a decade or more after surgery, without developing any recurrence, indicating
the benign nature of these neoplasms.
Keywords: Central neurocytoma - intraventicular - extraventricular - typical - atypical - synaptophysin
Asian Pac J Cancer Prev, 17 (3), 1565-1570

Introduction
Gliomas are the commonest central nervous system
(CNS) neoplasms worldwide including Asia and Africa
(Ahmad et al., 2010; Trabelsi et al., 2014; Zahir et al.,
2014). Central Neurocytoma is a rare tumor with a
favorable prognosis and is composed of uniform, small
round cells with neuronal differentiation. It is typically
located in the lateral ventricles of the brain especially
near the foramen of Monro but can also be located in the
third and even fourth ventricles, occurs mostly in young
adults and histologically corresponds to WHO Grade
II (Dodero et al., 2000; Figarella-Branger et al., 2007).
Extraventricular tumors with a similar histology and

located in the cerebral hemispheres or spinal cord are
called “extraventricular neurocytomas” or EVNs (Figarella
et al., 2007; Brat, 2010). EVNs need to be distinguished
from the usual more common oligodendrogliomas
which have a relatively worse prognosis (Atalay et
al., 2015). The tumor cells are mature neurons which
resemble neurocytes similar to those normally found in
the dentate fascia of hippocampus and in the cerebellum
and were first described as ‘ neuronal’ by Hassoun et al
in (Hassoun et al., 1993). In the past, the intraventricular
central neurocytomas were often confused with other
intraventricular tumors especially ependymomas,
oligodendrogliomas, subependymomal astrocytomas etc.
However, immunohistochemistry has greatly improved
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the diagnostic accuracy (Conrad et al., 2000). The tumor
cell nuclei have finely speckled chromatin and cytoplasm
is clear. Thus these tumors need to be distinguished from
other clear cell tumors (Bonney et al., 2015). Central
neurocytomas usually have Mib 1 (ki 67) labeling index
of less than 2%. Some central neurocytomas have an
index higher than 2%, histologically show mitoses,
vascular proliferation and/or necrosis, and demonstrate
a significantly shorter recurrence free interval. Such
tumors are called “atypical central neurocytomas”
(Soylemezoglu et al., 1997; Chou et al., 1999; Mackenzie,
1999). However, so far, such atypical lesions have not
been assigned a higher WHO grade. The same histologic
criteria and Mib 1 labeling index threshold can also be
used to designate extraventricular lesions-atypical EVNs
(Brat, 2010). Most cases reported in literature including
extraventricular and atypical neurocytomas are single
case reports or case series involving two or more cases.
The aim of this study is to present the cases of Central
(and extraventricular) Neurocytomas diagnosed in our
department, the largest center for histopathology in
Pakistan, over a period of almost 15 years. Our department
is a major referral center for challenging and difficult
cases covering all subspecialties including brain tumors,
from all over Pakistan. We hope that this series of cases
will be an important addition to the available literature
on these rare tumors.

Mib 1 (Ki 67)- monoclonal, ready to use, Dako cytomation,
Denmark, in most cases. In selected cases, Chromogranin
A, monoclonal, ready to use, Dako cytomation, Denmark;
and Cytokeratin AE1/AE3 (Monoclonal, ready to use,
Dako cytomation), Denmark were also used. All data
was analyzed using SPSS 19.0 version software package.

Results

Materials and Methods

A total of 35 cases of Central Neurocytoma were
reported during the study period (2001-2015). Out of
35, 21 patients (60%) were males while 14(40%) were
females. Male to fem ale ratio was 1:5:1. Age range
was 9 to 51 years. Mean and median age was 26 and
27 years respectively. Out of 35 cases, 31 (88.6%) were
intraventricular, while 4 (11.4%) were extraventricular. Of
the 31 intraventricular tumors, 29 (93.5%) were located
in the lateral ventricles and 2 (6.5%) were located in the
third ventricle. The 4 extraventricular tumors were located
in the corpus callosum, thalamus, left temporoparietal
hemisphere and the suprasellar region respectively.
Histologically, 6 out of 35 (17.1%) were compatible with
“atypical central neurocytoma.” Of these, 5 cases were
intraventricular in location while 1 case was located in
the corpus callosum. The other 29 tumors (82.9%) were
all histologically compatible with the usual grade II
central neurocytomas. Histologically, all cases showed
nests and/or sheets of uniform round cells with uniform
round to oval nuclei having finely speckled chromatin,

Slides of all cases reported as Neurocytomas
between Jan 1, 2001 and June 30, 2015 in the Section of
Histopathology, Department of Pathology and Laboratory
Medicine, Aga Khan University Hospital, Karachi were
retrieved and reviewed by the two principal authors
(ZA and NU). All cases were fixed in 10% buffered
formalin and embedded in paraffin wax. Sections were
cut at thickness of 5 microns and were routinely stained
with Hematoxylin and Eosin (H&E). Five microns thick
unstained sections were also cut from paraffin blocks
for performing Immnunohistochemistery (IHC). These
unstained sections were deparaffinized in xylene, hydrated
in decreasing concentrations of alcohol solution and
then washed in Tris Buffer. IHC staining was performed
using avidin-biotin-peroxidase method (Sigma, St Louis,
MO). IHC antibodies used included Glial Fibrillary
Acidic Protein (GFAP) polyclonal, ready to use -Dako
Corporation, (Carpenteria, California; Synaptophysinmonoclonal, Ready to use, Dako Cytomation, Denmark;

Figure 1. A) Typical Central neurocytoma exhibiting
uniform small cells with intervening chicken wire
vessels (H&E, 400x magnification) and B) perinuclear
halos (H&E, 400x magnification). C) Foci of nuclear
free zones (H&E, 200x magnification). The Ki 67 index
is less than 2% (D)

Table 1. Atypical Neurocytomas in Our Study (n=6)
Serial
Number
1
2
3
4
5
6

Location
Intraventricular
Extraventricular (suprasellar)
Intraventricular*
Intraventricular
Intraventricular**
Intraventricular*

Year of
surgery
2007
2010
2010
2012
2015
2015

Mitoses/10HPFs

Mib 1(Ki 67)

Follow up

3
>3
3
3
>3
>3

2-5%
>5%
>5%
2-5%
>5%
>5%

Not available
Died within a month after surgery
Not available
Alive and well. No recurrence
Alive and well. No recurrence
Alive and well. No recurrence

*Showed vascular proliferation on histological examination; ** Showed necrosis on histological examination
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Table 2. Immunohistochemical Staining in Our Cases (n=35)
Serial number
1
2
3
4
5
6
7
8
9
10

Immunohistochemical stain

Positive

Synaptophysin
GFAP
S 100 protein
Chromogranin A
Neuron specific enolase (NSE)
CD 56
Neurofilament (NF)
CD 99 (Mic 2)
Epithelial membrane antigen
(EMA)
Cytokeratin AE1/AE3

31 (86.6%)
9 (25.7%)
6 (17.1%)
8 (22.8%)
8 (22.8%)
3 (8.6%)
-

Negative

1 (2.9%)
21 (60%)
1 (2.9%)
8 (22.8%)
2 (5.8%)
1 (2.9%)
3 (8.6%)
8 (22.8%)

Not performed

3 (8.6%)

9 (25.7%)

23 (65.7%)

-

9 (25.7%)

26 (74.3%)

3 (8.6%)
5 (14.3%)
28 (80%)
19 (54.3%)
25 (71.4%)
31 (88.6%)
32 (91.4%)
27 (77.2%)

Table 3. Follow Up of Patients in Our Series (n=13)
Recurrence

Follow up

Ventricular
Ventricular
Ventricular
Ventricular
Ventricular

Radiation
treatment
No
No
No
No
No

No
No
No
Yes, in 2015
No

Atypical

Extraventricular

No

No

Typical
Atypical
Atypical
Typical
Typical
Typical
Atypical

Extraventricular
Ventricular
Ventricular
Ventricular
Extraventricular
Ventricular
Ventricular

Yes
No
Yes
Yes
No
No
Yes

No
No
No
No
No
No
No

Alive
Alive
Alive
Alive
Alive
Died within a
month of surgery
Alive
Alive
Alive
Alive
Alive
Alive
Alive

Serial Number

Year of surgery

Histology

Location

1
2
3
4
5

2002
2003
2004
2006
2009

Typical
Typical
Typical
Typical
Typical

6

2010

7
8
9
10
11
12
13

2010
2010
2012
2012
2012
2015
2015

Figure 2. A) An atypical central neurocytoma exhibiting
increased cellularity (H&E, 200x magnification). B)
Foci showing cytologic atypia and C) a single focus
of vascular proliferation is seen in small arrow(H&E,
400x magnification). Increased Ki 67 index (>10%)
is seen (D)

Figure 3. A) Foci of coarse calcification in central
neurocytoma (H&E, 200x magnification). B) Focus
of perivascular and C) Homer Wright rosettes
. D) Scattered ganglioid cells (large arrow) and
multinucleated giant cells (small arrow) [H&E, 400x
magnification]

inconspicuous nucleoli, and perinuclear cytoplasmic
clearing (perinuclear halos). All cases showed delicate,
fibrillary neuropil like matrix (Figure 1A-D). Among other
histological features, the 6 “atypical” cases demonstrated
cellular atypia, increased mitotic activity and Mib 1 (Ki
67) labeling indices above 2% (Figure 2A-D). However, 3

of the 6 showed >3 mitoses/10HPF while 4 of the 6 showed
Mib 1 labeling indices >5% (Table 1).Of these 6 atypical
neurocytomas, 3 showed microvascular proliferation and
1 case also showed necrosis (Figure 2C). These were the
only cases in the entire series which showed microvascular
proliferation and/or necrosis. Scattered mitotic activity
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and mild or focal atypia were seen in another 8 cases.
Hence, a total of 14 out of 35 cases (42.9%) showed at
least focal atypia and scattered mitotic activity. Capillary
sized vessels, arranged in many cases in a branching or
arborizing pattern were seen in 20 cases (57.1%). Foci
of calcification (Figure 3A) were seen in 12 out of 35
cases (34.3%). Less frequent histologic findings included
perivascular pseudorosettes (Figure 3B) seen in 7 cases
(20%), Homer Wright (Figure 3C) or true rosettes seen
in 3 cases (8.6%), and ganglioid cells (Figure 3D) seen
in only 1 out of the total 35 cases (2.9%).
In 19 (54.3%) out of 35 cases, the only clinical details
provided were those of an intraventricular tumor/mass. In
the remaining 16 cases, the clinical signs and symptoms
included headache (in 12(34.3%) cases), vomiting (in
3 cases), seizures (in 2 cases), urinary and/or fecal
incontinence (in 2 cases), difficulty in walking (in 2 cases)
and personality changes (in 2 cases). The following signs
and symptoms were seen in 1 case each: decrease in vision,
diplopia, papilledema, vertigo and pain in lower limb.
On immunohistochemistry, synaptophysin was the
most consistent and reliable marker being positive in
almost all cases in which it was performed. GFAP was
mostly negative but showed focal positivity in tumor cells
in some cases. The details of immunohistochemical stains
analyzed in our cases are shown in Table 2.
Follow up was unfortunately available in only 13 out
of 35 cases (37.1%). The details are shown in Table 3.

Discussion
The incidence rate of Central Nervous System (CNS)
neoplasms has risen more than 40% in the last two decades
(Zahir et al., 2014). Central neurocytomas are rare in our
practice and composed about 0.7% of all CNS neoplasms
in a study carried in our department (Ahmad et al., 2010).
In our series of 35 patients, 60% were males, mean age
was 26 years, 88.6% tumors were intraventricular, and
93.5% of intraventricular tumors were located in the
lateral ventricles. There were 4 extraventricular tumors
comprising 11.4% of the total while 6 (17.1%) were
histologically compatible with atypical neurocytomas
with Mib 1 (ki 67) levels greater than 2%. Only 1 of the 6
atypical neurocytomas was extraventricular. Studies have
shown that this tumor affects males and females almost
equally, and mainly affects young adults. Mean age was
29 years in one study (Tacconi et al., 1997; Conrad et
al., 2000; Figarella-Branger et al., 2007). Tacconi et al
published a series of 5 cases in 1997 and stressed the
importance of diagnostic suspicion, total surgical excision
and radiotherapy in the prognosis of this tumor (Tacconi
et al., 1997). In the year 2000, a number of studies were
published on central neurocytomas. Conrad et al published
a clinicopathological analysis of 3 cases in which they
discussed the clinical and radiological features, surgical
findings and pathological appearance of this tumor (Conrad
et al., 2000). The same year Dodero et al reported 2 cases
of ‘giant’ central neurocytomas in two young women with
both cases showing triventricular extension (Dodero et
al., 2000). In a series of 10 cases, Favereaux et al, also in
2000, discussed the histopathological variants of central
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neurocytoma. In their series, 2 out of 10 cases fulfilled
the histological criteria for atypical neurocytomas. These
2 cases showed less marked reactivity for the neuronal
marker Synaptophysin compared to the 8 “classical” cases.
Their 2 atypical cases were cellular with increased mitotic
activity. One case also showed tumor necrosis. Both their
atypical cases had Mib 1 labeling index >5.2% and both
tumors recurred. Based on this, they concluded that high
mitotic activity, necrosis, loss of neuronal differentiation
on immunohistochemistry and high Mib 1 labeling
index were the histological and immunohistochemical
criteria for aggressive behavior (Favereaux et al., 2000).
Chou et al reported a case of atypical neurocytoma. The
histology in their case showed up to 3 mitoses/10HPF
and Mib 1 labeling index was 5%. Their patient died
of hydrocephalus and brain edema the day after he
underwent partial resection. They noted that atypical
neurocytomas require postoperative radiotherapy (Chou et
al., 1999). In a comprehensive review published in 2006,
Sharma et al discussed the epidemiology, histogenesis,
clinical presentation, the characteristic neuroimaging
and histopathologic findings and the therapeutic options.
They concluded that safe maximal resection is the best
therapeutic option and shows the best long term results
when taking into account the local control of the tumor
and long term survival of the patient. They emphasized
the beneficial effect of adjuvant radiotherapy in atypical
neurocytomas and when the tumor is incompletely resected
(Sharma et al., 2006). Ulivieri and Oliveri described a
single case in a 25 year old male in 2007 (Ulivieri and
Oliveri, 2007). However, two relatively large series (of
9 cases each) were published in 2008. The first of these
published by Chen et al demonstrated high proliferative
index (Mib 1 labeling index upto 6.8%) in two patients in
whom the disease recurred. They also showed that apart
from high proliferation index, vascular proliferation and
synaptophysin expression were more prominent in the
recurrent tumors compared to the primary. However,
they concluded that recurrent tumors are usually local
and patients undergo full recovery following a second
surgical resection and radiotherapy (Chen et al., 2008).
This indicates that Mib 1 (Ki 67) labeling index is a
valuable prognostic factor in Neurocytomas, and not just
in gliomas, where its role as a prognostic factor is well
established (Chen W-T et al., 2015). The other study by
Chen et al, which also looked at nine cases, followed
the patients for 8 to 33 months after surgery and used
various methods to assess the functional outcomes of
central neurocytomas. They found that most of the patients
achieved good functional outcomes and showed good
ability to perform their daily activities independently.
They recommended that although these tumors are mostly
benign, patients should be regularly followed up in order
to detect any recurrence of the tumor (Chen et al., 2008).
A multidisciplinary review by Chodhari et al published
in 2009 concluded that recurrence rate for central
neurocytomas after surgery was more common than
previously thought. The authors therefore recommended
a multi-modality team involvement for optimum
management of these tumors (Chodhari et al., 2009).
Chen et al published a series of ten cases in 2012, nine
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of which were located in the lateral ventricles while one
case was extraventricular (in the sellar region). Following
surgical resection, six patients (four with subtotal and
two with total resection) received radiotherapy. None of
the tumors in their series recurred (Chen et al., 2012).
Kane et al published a remarkably large series in 2012
solely on intracranial extraventricular neurocytomas
(EVNs). This series comprised 85 patients of whom
27% had atypical EVNs on histologic examination. The
authors demonstrated the better prognosis of typical
EVNs compared to atypical EVNs following surgical
resection. According to their findings typical EVNs had
a 5-year recurrence rate of 36% and a 5 year mortality
rate of 4% compared to 5 year recurrence rate of 68%
and 5 year mortality rate of 44% for atypical EVNs. The
difference was statistically significant (p <0.001). They
also found that for both typical and atypical EVNs, gross
total resection was more beneficial compared to subtotal
resection and that radiotherapy (in both typical and
atypical EVNs) benefited patients with subtotal resection
of the primary tumor (Kane et al., 2012). Canova at al
noted that the main treatment of central neurocytomas
which is total resection is achieved in only half the cases.
They argue that external beam radiotherapy was beneficial
in patients with subtotal resection as well as in those
with atypical central neurocytomas. They also discussed
the role of chemotherapy in patients with extracranial
and/or neuromeningeal spread of the tumor, and in
tumors which recurred after surgery and/or radiotherapy
(Canova at al., 2014). In a recent study published in 2015,
Bonney et al looked at the molecular biology of central
neurocytomas and acknowledged that although progress
on this front was being made, this had not yet translated
into the development of targeted therapies for these tumors
(Bonney et al., 2015). A recent 2015 article by Yang et
al focused on the clinical manifestations of these tumors
and concluded that although no clinical feature was
pathognomonic, patients typically presented with signs
and symptoms of increased intracranial pressure (Yang
et al., 2015). Other authors also agree that manifestations
of increased intracranial pressure usually brought these
tumors to clinical attention (Chen et al., 2008; Chen et al.,
2012; Canova et al., 2014). Kawano et al recently reported
a case of atypical EVN in a 3 year old girl. Atypical EVN
in children are extremely rare. However, the authors argue
that atypical EVN should be considered in the differential
diagnosis of an intracranial but extraventricular cystic
tumor in children (Kawano et al., 2015).
In a comprehensive review on extraventricular
neurocytomas, published in 2014, Patil et al discussed
the clinical and pathologic features of these tumors, the
effectiveness of surgical resection and progression free
survival. Of their seven cases, ages 7 to 65 years, four
were located in the cerebral hemispheres, and 1 each in
the cerebellum, pineal gland and spinal cord. They found
that gross total resection and subtotal resection plus
radiotherapy had similar outcomes, while extremes of age
and atypical histology adversely affected the prognosis
(Patil et al., 2014). A recent article by Sweiss et al also
reviewed EVNs including their epidemiology, clinical and
radiological findings, locations, treatment and prognosis

and concluded that being quite rare, the epidemiology of
EVNs was not definitely known and they were associated
with a poor prognosis compared to central neurocytomas.
They argued that effective treatment strategies for these
rare tumors were still lacking (Sweiss et al., 2015).
The detailed discussion above clearly highlights the
importance of adjuvant radiotherapy in the treatment of
both central and extraventricular neurocytomas especially
in the presence of subtotal resection. Various studies
discussed above clearly demonstrate that radiotherapy
increases local control of the tumor. However, a study by
Vrana et al in 2013, while acknowledging the usefulness
and importance of adjuvant radiotherapy in neurocytomas
cautioned that the timing of radiotherapy in these patients
needed to be considered carefully to protect these patients
from possible late side effects of radiotherapy since most
patients with neurocytomas have long time survival
following treatment (Vrana et al., 2013).
In addition to the usual microscopic findings, rare
features such as Homer Wright and true rosettes and
ganglioid cells were seen in 3 and 1 of our 35 cases
respectively. These rare features have been described in
these tumors (Robbins et al., 1995).
Synaptophysin is the most reliable immunohistochemical
marker in these tumors and diffuse positivity is seen in the
neuropil, the fibrillary zones and perivascular nuclear-free
zones (Figarella-Branger et al., 1992). Synaptophysin
was also the best marker in our series being positive in
almost all cases in which it was performed. Neu N and
anti-HU antibodies are also considered to be very useful
and demonstrate nuclear staining in most cases (Gultekin
et al., 1998; Soylemezoglu et al., 2003). Unfortunately,
we do not have Neu N and anti-HU antibodies in our
immunohistochemistry panel as there are issues of
financial feasibility. GFAP staining has been mostly
reported in trapped reactive astrocytes, however some
authors have reported GFAP positivity in tumor cells
(von Deimling et al., 1990). As shown in the results,
GFAP positivity was seen in focal cells in over 25% of
our cases. Chromogranin A and Neurofilament are usually
negative in central neurocytomas (Hassoun et al., 1993).
Neurofilament was performed in only 3 of our cases and
was negative in all 3. However, chromogranin A which
was performed in almost 45% of our cases was positive
in half of these. It also needs to be noted that diffuse,
widespread expression of the immunohistochemical stain
OLIG 2 helps in differentiating central neurocytomas
(usually negative or focally positive in a minority of cases)
and clear cell ependymomas from oligodendrogliomas
(widespread OLIG 2 expression in almost all cases
(Preusser et al., 2007).
Follow up was available in only 13 out of 35 cases.
This is unfortunate but perhaps inevitable considering
that we receive cases from all over Pakistan, a country
of 180 million people, and many cases come from far
off and remote areas. A glance at Table 3 shows that 12
out of 13 patients (in whom follow up was available)
were alive at the time of follow up. Of the 4 patients
with atypical neurocytomas (in whom follow up was
available), 1 patient died within a month of surgery (in
2010). This tumor was extraventricular and the patient
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most likely died of complications arising after surgery.
Of the other 3 patients (operated in 2010, 2012 and
2015), 2 received postoperative radiation, all 3 were
alive with no recurrence. Of all 13 patients, only 1 patient
with an intraventricular typical central neurocytoma
recently developed recurrence (in 2015), almost 9 years
after surgery in 2006. This patient had not received any
radiation treatment following initial surgery. Overall, out
of 13, only 5 patients received radiation (all with surgery
in 2010 or later). However, as shown in Table 2, patients
with initial surgery as far back as 2002 and 2003, who
did not receive any radiation treatment, are all alive and
well at the time of recent follow up. The 3 patients with
‘atypical’ neurocytomas also were alive and well at follow
up. All had surgery witin the last three years (2 of them
in 2015). They need to be followed for a longer time to
determine their clinical behavior.
In conclusion, we present a series of 35 cases of
neurocytoma including extraventicular and atypical
neurocytomas that were diagnosed in our department
over a period of almost 15 years. We hope that our series
will be an important addition to the available literature
on these rare tumors.
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